巨噬细胞移动抑制因子在肝细胞癌中的研究进展

Research progress on macrophage migration inhibitory factor in hepatocellular carcinoma

  • 摘要: 巨噬细胞移动抑制因子(MIF)是具有促炎和致癌双向作用的重要细胞因子。MIF异常表达可介导多条信号通路的异常激活进而导致肝细胞癌(HCC)的发生,其机制涉及细胞增殖与转移、调控凋亡和自噬以及新生血管形成等过程。目前,中晚期HCC患者的临床治疗基本以介入治疗和多靶点分子靶向药物治疗为主,但其效果比较局限。因此寻找新的治疗靶点,开发新型抗HCC药物是目前肝癌治疗领域的研究热点。本文就MIF诱导HCC发生及恶性进展的具体作用机制及其作为HCC潜在治疗靶点的研究进展进行综述,以期为HCC的治疗提供参考。

     

    Abstract: Macrophage migration inhibitory factor (MIF) is an important cytokine with dual pro-inflammatory and pro-carcinogenic roles. Aberrant expression of MIF can mediate abnormal activation of multiple signaling pathways and cause the occurrence of hepatocellular carcinoma (HCC), and its mechanisms involve processes such as cell proliferation and migration, regulation of apoptosis and autophagy, and neovascularization. Currently, the clinical treatments for patients with advanced HCC mainly rely on interventional therapy and multi-targeted molecular drugs, but the efficacy is relatively limited. Therefore, finding new therapeutic targets and developing novel anti-HCC drugs are the hot topics in the field of liver cancer treatment currently. This paper reviewed the specific mechanisms on occurrence and malignant progression of MIF-induced HCC as well as its potential as a therapeutic target for HCC, with the aim of providing references for the treatment of HCC.

     

/

返回文章
返回